Yash Sodhi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yash Sodhi has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- James B. Doub
The Doub Laboratory of Translational Bacterial Research, University of Maryland School of Medicine, Baltimore, MD 21201, USA
1 shared publication - Lila Berle
Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH, 9000 Rockville Pike, Bethesda, Maryland 20892, United States
1 shared publication - Nazary Nebeluk
Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medi-cine, Baltimore, Maryland, USA, USA
1 shared publication - Poonam Mathur
Institute of Human Virology University of Maryland School of Medicine Baltimore Maryland USA
1 shared publication
Latest Publications
- Open Access
- 30 April 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (2) , 226
Repurposing Non-Infectious Therapeutic Agents to Aid in the Treatment of Chronic Biofilm Infections
Antibiotics primarily exert their effect on planktonic microbial states, limiting their ability to eradicate biofilms commonly seen in chronic infections. This is because the minimal inhibitory concentration of antibiotics needed to kill microbes in biofilms can be up to 1000 times greater than when microbes are in their planktonic state. Yet up to 70% of all chronic infections are associated with a biofilm component. Consequently, novel therapeutics are needed to aid in the treatment of chronic biofilm infections. One such approach is to repurpose drugs that have demonstrated safety for non-infectious clinical indications. The main advantage of this approach is that the agents have already been shown to be safe for human administration, which can expedite clinical trial development of agents for biofilm infections. Unfortunately, most clinicians are unaware of the antimicrobial properties of some commonly used drugs. Thus, the aim of this Perspective was to discuss the potential of four drugs that have theoretical promise as adjuvants in the treatment of chronic biofilm infections. This was accomplished by providing detailed discussion of each agent with respect to current clinical use, potential mechanisms of antimicrobial activity, and present data to support use as adjuvant biofilm agents.
- 30 April 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (2) , 226
Open AccessRepurposing Non-Infectious Therapeutic Agents to Aid in the Treatment of Chronic Biofilm Infections
Antibiotics primarily exert their effect on planktonic microbial states, limiting their ability to eradicate biofilms commonly seen in chronic infections. This is because the minimal inhibitory concentration of antibiotics needed to kill microbes in biofilms can be up to 1000 times greater than when microbes are in their planktonic state. Yet up to 70% of all chronic infections are associated with a biofilm component. Consequently, novel therapeutics are needed to aid in the treatment of chronic biofilm infections. One such approach is to repurpose drugs that have demonstrated safety for non-infectious clinical indications. The main advantage of this approach is that the agents have already been shown to be safe for human administration, which can expedite clinical trial development of agents for biofilm infections. Unfortunately, most clinicians are unaware of the antimicrobial properties of some commonly used drugs. Thus, the aim of this Perspective was to discuss the potential of four drugs that have theoretical promise as adjuvants in the treatment of chronic biofilm infections. This was accomplished by providing detailed discussion of each agent with respect to current clinical use, potential mechanisms of antimicrobial activity, and present data to support use as adjuvant biofilm agents.